Abstract
The median life expectancy for cystic fibrosis is now over 30 years, and it is projected that in newborn infants it will become more than 40 years. The identification of the cystic fibrosis gene and its product, cystic fibrosis transmembrane conductance regulator (CFTR), has widened the spectrum of the disease from the classical case of the infant with cystic fibrosis to the elderly childless man with unexplained bronchiectasis. There is increasing evidence of the advantages of newborn screening for cystic fibrosis and subsequent specialist care. Management concentrates on optimising nutritional status and preventing lung infection and inflammation.
MeSH terms
-
Adolescent
-
Adult
-
Animals
-
Anti-Bacterial Agents / therapeutic use
-
Child
-
Child, Preschool
-
Cystic Fibrosis / genetics*
-
Cystic Fibrosis / physiopathology
-
Cystic Fibrosis / therapy
-
Cystic Fibrosis Transmembrane Conductance Regulator / genetics
-
Cystic Fibrosis Transmembrane Conductance Regulator / physiology
-
Delivery of Health Care
-
Genetic Testing / methods
-
Genetic Therapy / methods
-
Genotype
-
Humans
-
Infant
-
Infant, Newborn
-
Life Expectancy
-
Lung Transplantation / methods
-
Macrolides
-
Mice
-
Opportunistic Infections / complications
-
Phenotype
-
Prognosis
-
Tobramycin / therapeutic use
Substances
-
Anti-Bacterial Agents
-
CFTR protein, human
-
Macrolides
-
Cystic Fibrosis Transmembrane Conductance Regulator
-
Tobramycin